Cancer Immunology, Immunotherapy

, Volume 56, Issue 11, pp 1795–1805 | Cite as

Immunogenicity of the carcinoembryonic antigen derived peptide 694 in HLA-A2 healthy donors and colorectal carcinoma patients

  • Pedro M. S. Alves
  • Sebastien Viatte
  • Theres Fagerberg
  • Olivier Michielin
  • Gabriel Bricard
  • Hanifa Bouzourene
  • Henri Vuilleumier
  • Thorsten Kruger
  • Jean-Claude Givel
  • Frédéric Lévy
  • Daniel E. Speiser
  • Jean-Charles Cerottini
  • Pedro Romero
Original Article


Carcinoembryonic antigen (CEACAM5) is commonly overexpressed in human colon cancer. Several antigenic peptides recognized by cytolytic CD8+ T-cells have been identified and used in colon cancer phase-I vaccination clinical trials. The HLA-A*0201-binding CEA694–702 peptide was recently isolated from acid eluted MHC-I associated peptides from a human colon tumor cell line. However, the immunogenicity of this peptide in humans remains unknown. We found that the peptide CEA694–702 binds weakly to HLA-A*0201 molecules and is ineffective at inducing specific CD8+ T-cell responses in healthy donors. Immunogenic-altered peptide ligands with increased affinity for HLA-A*0201 were identified. Importantly, the elicited cytolytic T lymphocyte (CTL) lines and clones cross-reacted with the wild-type CEA694–702 peptide. Tumor cells expressing CEA were recognized in a peptide and HLA-A*0201 restricted fashion, but high-CEA expression levels appear to be required for CTL recognition. Finally, CEA-specific T-cell precursors could be readily expanded by in vitro stimulation of peripheral blood mononuclear cell (PBMC) from colon cancer patients with altered CEA peptide. However, the CEA-specific CD8+ T-cell clones derived from cancer patients revealed low-functional avidity and impaired tumor-cell recognition. Together, using T-cells to demonstrate the processing and presentation of the peptide CEA694-702, we were able to corroborate its presentation by tumor cells. However, the low avidity of the specific CTLs generated from cancer patients as well as the high-antigen expression levels required for CTL recognition pose serious concerns for the use of CEA694-702 in cancer immunotherapy.


CTL Tumor immunology Cancer vaccines Tetramers 







Monoclonal antibody


Mean fluorescence intensity


Not done


Polymerase chain reaction



This study was supported in part by Swiss National Science Foundation special program NCCR Molecular Oncology. We would like to acknowledge the technical support of Estelle Devevre and Frederic Grosjean and Nicole Montandon.


  1. 1.
    Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer-Williams MG, Bell JI, McMichael AJ, Davis MM (1996) Phenotypic analysis of antigen-specific T lymphocytes. Science 274:94–96PubMedCrossRefGoogle Scholar
  2. 2.
    Alves PM, Faure O, Graff-Dubois S, Cornet S, Bolonakis I, Gross DA, Miconnet I, Chouaib S, Fizazi K, Soria JC, Lemonnier FA, Kosmatopoulos K (2006) Steap, a prostate tumor antigen, is a target of human CD8(+) T cells. Cancer Immunol Immunother 55:1504–1514CrossRefGoogle Scholar
  3. 3.
    Alves PM, Faure O, Graff-Dubois S, Gross DA, Cornet S, Chouaib S, Miconnet I, Lemonnier FA, Kosmatopoulos K (2003) Epha2 as target of anticancer immunotherapy: identification of HLA-A*0201-restricted epitopes. Cancer Res 63:8476–8480PubMedGoogle Scholar
  4. 4.
    Ayyoub M, Migliaccio M, Guillaume P, Lienard D, Cerottini JC, Romero P, Levy F, Speiser DE, Valmori D (2001) Lack of tumor recognition by Htert peptide 540–548-specific CD8(+) T cells from melanoma patients reveals inefficient antigen processing. Eur J Immunol 31:2642–2651PubMedCrossRefGoogle Scholar
  5. 5.
    Berinstein NL (2002) Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: a review. J Clin Oncol 20:2197–2207PubMedCrossRefGoogle Scholar
  6. 6.
    Dalerba P, Maccalli C, Casati C, Castelli C, Parmiani G (2003) Immunology and immunotherapy of colorectal cancer. Crit Rev Oncol Hematol 46:33–57PubMedCrossRefGoogle Scholar
  7. 7.
    Dupont J, Latouche JB, Ma C, Sadelain M (2005) Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells. Cancer Res 65:5417–5427PubMedCrossRefGoogle Scholar
  8. 8.
    Eidelman FJ, Fuks A, DeMarte L, Taheri M, Stanners CP (1993) Human carcinoembryonic antigen, an intercellular adhesion molecule, blocks fusion and differentiation of rat myoblasts. J Cell Biol 123:467–475PubMedCrossRefGoogle Scholar
  9. 9.
    Faure O, Graff-Dubois S, Bretaudeau L, Derre L, Gross DA, Alves PM, Cornet S, Duffour MT, Chouaib S, Miconnet I, Gregoire M, Jotereau F, Lemonnier FA, Abastado JP, Kosmatopoulos K (2004) Inducible Hsp70 as target of anticancer immunotherapy: identification of HLA-A*0201-restricted epitopes. Int J Cancer 108:863–870PubMedCrossRefGoogle Scholar
  10. 10.
    Fong L, Hou Y, Rivas A, Benike C, Yuen A, Fisher GA, Davis MM, Engleman EG (2001) Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci USA 98:8809–8814PubMedCrossRefGoogle Scholar
  11. 11.
    Goldberg AL, Cascio P, Saric T, Rock KL (2002) The importance of the proteasome and subsequent proteolytic steps in the generation of antigenic peptides. Mol Immunol 39:147–164PubMedCrossRefGoogle Scholar
  12. 12.
    Graham RA, Wang S, Catalano PJ, Haller DG (1998) Postsurgical surveillance of colon cancer: preliminary cost analysis of physician examination, carcinoembryonic antigen testing, chest X-ray, and colonoscopy. Ann Surg 228:59–63PubMedCrossRefGoogle Scholar
  13. 13.
    Hammarstrom S (1999) The carcinoembryonic antigen (Cea) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 9:67–81PubMedCrossRefGoogle Scholar
  14. 14.
    Herin M, Lemoine C, Weynants P, Vessiere F, Van Pel A, Knuth A, Devos R, Boon T (1987) Production of stable cytolytic T-cell clones directed against autologous human melanoma. Int J Cancer 39:390–396PubMedCrossRefGoogle Scholar
  15. 15.
    Hernandez J, Lee PP, Davis MM, Sherman LA (2000) The use of HLA A2.1/P53 peptide tetramers to visualize the impact of self tolerance on the Tcr repertoire. J Immunol 164:596–602PubMedGoogle Scholar
  16. 16.
    Jessup JM, Petrick AT, Toth CA, Ford R, Meterissian S, O’Hara CJ, Steele GJ, Thomas P (1993) Carcinoembryonic antigen: eanhancement of liver colonisation through retention of human colorectal carcinoma cells. Br J Cancer 67:464–470PubMedGoogle Scholar
  17. 17.
    Kreuwel HT, Sherman LA (2001) The T-cell repertoire available for recognition of self-antigens. Curr Opin Immunol 13:639–643PubMedCrossRefGoogle Scholar
  18. 18.
    Kuroki M, Arakawa F, Matsuo Y, Oikawa S, Misumi Y, Nakazato H, Matsuoka Y (1991) Molecular cloning of nonspecific cross-reacting antigens in human granulocytes. J Biol Chem 266:11810–11817PubMedGoogle Scholar
  19. 19.
    Machlenkin A, Paz A, Bar Haim E, Goldberger O, Finkel E, Tirosh B, Volovitz I, Vadai E, Lugassy G, Cytron S, Lemonnier F, Tzehoval E, Eisenbach L (2005) Human Ctl epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy. Cancer Res 65:6435–6442PubMedCrossRefGoogle Scholar
  20. 20.
    Marshall J (2003) Carcinoembryonic antigen-based vaccines. Semin Oncol 30:30–36PubMedCrossRefGoogle Scholar
  21. 21.
    Montes M, Rufer N, Appay V, Reynard S, Pittet MJ, Speiser DE, Guillaume P, Cerottini JC, Romero P, Leyvraz S (2005) Optimum in vitro expansion of human antigen-specific CD8 T cells for adoptive transfer therapy. Clin Exp Immunol 142:292–302PubMedCrossRefGoogle Scholar
  22. 22.
    Nagel G, Grunert F, Kuijpers TW, Watt SM, Thompson J, Zimmermann W (1993) Genomic organization, splice variants and expression of Cgm1, a CD66-related member of the carcinoembryonic antigen gene family. Eur J Biochem 214:27–35PubMedCrossRefGoogle Scholar
  23. 23.
    Nap M, Mollgard K, Burtin P, Fleuren GJ (1988) Immunohistochemistry of carcino-embryonic antigen in the embryo, fetus and adult. Tumour Biol 9:145–153PubMedCrossRefGoogle Scholar
  24. 24.
    Overwijk WW, Tsung A, Irvine KR, Parkhurst MR, Goletz TJ, Tsung K, Carroll MW, Liu C, Moss B, Rosenberg SA, Restifo NP (1998) Gp100/Pmel 17 is a murine tumor rejection antigen: induction of “self”-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med 188:277–286PubMedCrossRefGoogle Scholar
  25. 25.
    Parham P, Brodsky FM (1981) Partial purification and some properties of Bb7.2. A cytotoxic monoclonal antibody with specificity for HLA-A2 and a variant of HLA-A28. Hum Immunol 3:277–299PubMedCrossRefGoogle Scholar
  26. 26.
    Parker KC, Bednarek MA, Coligan JE (1994) Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 152:163–175PubMedGoogle Scholar
  27. 27.
    Parkhurst MR, Riley JP, Igarashi T, Li Y, Robbins PF, Rosenberg SA (2004) Immunization of patients with the Htert:540–548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase. Clin Cancer Res 10:4688–4698PubMedCrossRefGoogle Scholar
  28. 28.
    Princiotta MF, Finzi D, Qian SB, Gibbs J, Schuchmann S, Buttgereit F, Bennink JR, Yewdell JW (2003) Quantitating protein synthesis, degradation, and endogenous antigen processing. Immunity 18:343–354PubMedCrossRefGoogle Scholar
  29. 29.
    Ramakrishna V, Ross MM, Petersson M, Gatlin CC, Lyons CE, Miller CL, Myers HE, McDaniel M, Karns LR, Kiessling R, Parmiani G, Flyer DC (2003) Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells. Int Immunol 15:751–763PubMedCrossRefGoogle Scholar
  30. 30.
    Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S (1999) SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50:213–219PubMedCrossRefGoogle Scholar
  31. 31.
    Rodeberg DA, Nuss RA, Elsawa SF, Celis E (2005) Recognition of six-transmembrane epithelial antigen of the prostate-expressing tumor cells by peptide antigen-induced cytotoxic T lymphocytes. Clin Cancer Res 11:4545–4552PubMedCrossRefGoogle Scholar
  32. 32.
    Scardino A, Gross DA, Alves P, Schultze JL, Graff-Dubois S, Faure O, Tourdot S, Chouaib S, Nadler LM, Lemonnier FA, Vonderheide RH, Cardoso AA, Kosmatopoulos K (2002) Her-2/Neu and HTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. J Immunol 168:5900–5906PubMedGoogle Scholar
  33. 33.
    Schirle MKW, Weber B, Gouttefangeas C, Dumrese T, Becker HD, Stevanovic S, Rammensee HG (2000) Identification of tumor-associated MHC class I ligands by a novel T cell-independent approach. Eur J Immunol 30:2216–2225PubMedCrossRefGoogle Scholar
  34. 34.
    Screaton RA, Penn LZ, Stanners CP (1997) Carcinoembryonic antigen, a human tumor marker, cooperates with Myc and Bcl-2 in cellular transformation. J Cell Biol 137:939–952PubMedCrossRefGoogle Scholar
  35. 35.
    Shaw AR, Chan JK, Reid S, Seehafer J (1985) Hla-Dr synthesis induction and expression in HLA-Dr-negative carcinoma cell lines of diverse origins by interferon-gamma but not by interferon-beta. J Natl Cancer Inst 74:1261–1268PubMedGoogle Scholar
  36. 36.
    Skipper JC, Gulden PH, Hendrickson RC, Harthun N, Caldwell JA, Shabanowitz J, Engelhard VH, Hunt DF, Slingluff CLJ (1999) Mass-spectrometric evaluation of HLA-A*0201-associated peptides identifies dominant naturally processed forms of Ctl epitopes from Mart-1 and Gp100. Int J Cancer 82:669–677PubMedCrossRefGoogle Scholar
  37. 37.
    Speiser DE, Pittet MJ, Guillaume P, Lubenow N, Hoffman E, Cerottini JC, Romero P (2004) Ex vivo analysis of human antigen-specific CD8(+) T-cell responses: quality assessment of fluorescent HLA-A2 multimer and interferon-gamma elispot assays for patient immune monitoring. J Immunother 27:298–308PubMedCrossRefGoogle Scholar
  38. 38.
    Thompson JA, Grunert F, Zimmermann W (1991) Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. J Clin Lab Anal 5:344–366PubMedCrossRefGoogle Scholar
  39. 39.
    Tourdot S, Scardino A, Saloustrou E, Gross DA, Pascolo S, Cordopatis P, Lemonnier FA, Kosmatopoulos K (2000) A general strategy to enhance immunogenicity of low-affinity HLA-A2. 1-associated peptides: implication in the identification of cryptic tumor epitopes. Eur J Immunol 30:3411–3421PubMedCrossRefGoogle Scholar
  40. 40.
    Valmori D, Fonteneau JF, Lizana CM, Gervois N, Lienard D, Rimoldi D, Jongeneel V, Jotereau F, Cerottini JC, Romero P (1998) Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/Mart-1 immunodominant peptide analogues. J Immunol 160:1750–1758PubMedGoogle Scholar
  41. 41.
    Valmori D, Gileadi U, Servis C, Dunbar PR, Cerottini JC, Romero P, Cerundolo V, Levy F (1999) Modulation of proteasomal activity required for the generation of a cytotoxic T lymphocyte-defined peptide derived from the tumor antigen Mage-3. J Exp Med 189:895–906PubMedCrossRefGoogle Scholar
  42. 42.
    Van den Eynde B, Hainaut P, Herin M, Knuth A, Lemoine C, Weynants P, van der Bruggen P, Fauchet R, Boon T (1989) Presence on a human melanoma of multiple antigens recognized by autologous CTL. Int J Cancer 44:634–640PubMedCrossRefGoogle Scholar
  43. 43.
    Van Der Bruggen P, Zhang Y, Chaux P, Stroobant V, Panichelli C, Schultz ES, Chapiro J, Van Den Eynde BJ, Brasseur F, Boon T (2002) Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev 188:51–64CrossRefGoogle Scholar
  44. 44.
    Vonderheide RH, Hahn WC, Schultze JL, Nadler LM (1999) The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 10:673–679PubMedCrossRefGoogle Scholar
  45. 45.
    Yee C, Savage PA, Lee PP, Davis MM, Greenberg PD (1999) Isolation of high avidity melanoma-reactive Ctl from heterogeneous populations using peptide-Mhc tetramers. J Immunol 162:2227–2234PubMedGoogle Scholar
  46. 46.
    Yewdell JW (2001) Not such a dismal science: the economics of protein synthesis, folding, degradation and antigen processing. Trends Cell Biol 11:294–297PubMedCrossRefGoogle Scholar
  47. 47.
    Zhu MZ, Marshall J, Cole D, Schlom J, Tsang KY (2000) Specific cytolytic T-cell responses to human Cea from patients immunized with recombinant Avipox-Cea vaccine. Clin Cancer Res 6:24–33PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Pedro M. S. Alves
    • 1
    • 2
    • 3
  • Sebastien Viatte
    • 2
    • 3
  • Theres Fagerberg
    • 2
    • 6
  • Olivier Michielin
    • 2
    • 6
    • 7
  • Gabriel Bricard
    • 1
  • Hanifa Bouzourene
    • 4
  • Henri Vuilleumier
    • 5
  • Thorsten Kruger
    • 5
  • Jean-Claude Givel
    • 5
  • Frédéric Lévy
    • 2
  • Daniel E. Speiser
    • 1
  • Jean-Charles Cerottini
    • 2
  • Pedro Romero
    • 1
  1. 1.Division of Clinical Onco-ImmunologyLudwig Institute for Cancer Research, Hôpital Orthopédique, HO-05LausanneSwitzerland
  2. 2.Ludwig Institute for Cancer Research, Lausanne BranchUniversity of LausanneEpalingesSwitzerland
  3. 3.Molecular OncologyNational Center for Competence in Research (NCCR)LausanneSwitzerland
  4. 4.Institut Universitaire de PathologieCentre Hospitalier Universitaire VaudoisLausanneSwitzerland
  5. 5.Department of SurgeryCentre Hospitalier Universitaire VaudoisLausanneSwitzerland
  6. 6.Swiss Institute of BioInformaticsBaselSwitzerland
  7. 7.Multidisciplinary Oncology CenterLausanne University HospitalLausanneSwitzerland

Personalised recommendations